Alonso Vilches-Flores

Dr. Alonso Vilches-Flores

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
RSRicardo Xopan Suárez-García
Ricardo Xopan Suárez-García
QCQuetzal Chavez Castañeda
Quetzal Chavez Castañeda
RORodrigo Orrico-Pérez
Rodrigo Orrico-Pérez
SVSebastián Valencia-Marin
Sebastián Valencia-Marin
ACAri Evelyn Castañeda-Ramírez
Ari Evelyn Castañeda-Ramírez
HCHector Ivan Saldivar Ceron
Hector Ivan Saldivar Ceron
DIALOGUE (DIagnostic AI Learning through Objective Guided User Experience) is a generative artificial intelligence (GenAI)-based training program designed to enhance diagnostic communication skills in medical students. In this single-arm pre–post study, we evaluated whether DIALOGUE could improve students’ ability to disclose a type 2 diabetes mellitus (T2DM) diagnosis with clarity, structure, and empathy. Thirty clinical-phase students completed two pre-test virtual encounters with an AI-simulated patient (ChatGPT, GPT-4o), scored by blinded raters using an eight-domain rubric. Participants then engaged in ten asynchronous GenAI scenarios with automated natural-language feedback. Seven days later, they completed two post-test consultations with human standardized patients, again evaluated with the same rubric. Mean total performance increased by 36.7 points (95% CI: 31.4–42.1; p < 0.001), and the proportion of high-performing students rose from 0% to 70%. Gains were significant across all domains, most notably in opening the encounter, closure, and diabetes specific explanation. Multiple regression showed that lower baseline empathy (β = −0.41, p = 0.005) and higher digital self-efficacy (β = 0.35, p = 0.016) independently predicted greater improvement; gender had only a marginal effect. Cluster analysis revealed three learner profiles, with the highest-gain group characterized by low empathy and high digital self-efficacy. Inter-rater reliability was excellent (ICC ≈ 0.90). These findings provide empirical evidence that GenAI-mediated training can meaningfully enhance diagnostic communication and may serve as a scalable, individualized adjunct to conventional medical education.

4 March 2020 in Nutrition & Diabetes
Verified
Journal Article
Open access
PDF file
LNLesly Nava-Molina
Lesly Nava-Molina
TUToyokazu Uchida-Fuentes
Toyokazu Uchida-Fuentes
HRHéctor Ramos-Tovar
Héctor Ramos-Tovar
MFMartha Fregoso-Padilla
Martha Fregoso-Padilla
MRMarco Aurelio Rodríguez-Monroy
Marco Aurelio Rodríguez-Monroy
AVAlonso Vilches-Flores
Alonso Vilches-Flores
Backgrouds: Cannabinoid receptor antagonists have been suggested as a novel treatment for obesity and diabetes. We have developed a synthetic cannabinoid receptor antagonist denominated BAR-1. As the function and integrity of a β-cell cellular structure are important keys for diabetes onset, we evaluated the effects of pharmacological administration of BAR-1 on prediabetic and diabetic rodents.Methods: CD-1 mice fed a hypercaloric diet or treated with streptozotocin were treated with 10 mg/kg BAR-1 for 2, 4 or 8 weeks. Body weight, oral glucose tolerance test, HbA1c, triglycerides and insulin in serum were measured. In isolated islets, we evaluated stimulated secretion and mRNA expression, and relative area of islets in fixed pancreases. Docking analysis of BAR-1 was complemented.Results: BAR-1 treatment slowed down weight gain in prediabetic mice. Fasting glucose–insulin relation also decreased in BAR-1-treated mice and glucose-stimulated insulin secretion was increased in isolated islets, without effects in oral test. Diabetic mice treated with BAR-1 showed a reduced glucose and a partial recovery of islet integrity. Gene expression of insulin and glucagon showed biphasic behaviour, increasing after 4 weeks of BAR-1 administration; however, after 8 weeks, mRNA abundance decreased significantly. Administration of BAR-1 also prevents changes in endocannabinoid element expression observed in prediabetic mice. No changes were detected in other parameters studied, including the histological structure. A preliminary in-silico study suggests a close interaction with CB1 receptor.Conclusions: BAR-1 induces improvement of islet function, isolated from both prediabetic and diabetic mice. Effects of BAR-1 suggest a possible interaction with other cannabinoid receptors.

4 January 2023 in Islets
Verified
Journal Article
Open access
ECEdgardo Cortes-Justo
Edgardo Cortes-Justo
SGSergio H Garfias-Ramírez
Sergio H Garfias-Ramírez
AVAlonso Vilches-Flores
Alonso Vilches-Flores
The following review focuses on the scientific studies related to the role of endocannabinoid system (ECS) in pancreatic islet physiology and dysfunction. Different natural or synthetic agonists and antagonists have been suggested as an alternative treatment for diabetes, obesity and metabolic syndrome. Therapeutic use of Cannabis led to the discovery and characterization of the ECS, a signaling complex involved in regulation of various physiological processes, including food intake and metabolism. After the development of different agonists and antagonists, evidence have demonstrated the presence and activity of cannabinoid receptors in several organs and tissues, including pancreatic islets. Insulin and glucagon expression, stimulated secretion, and the development of diabetes and other metabolic disorders have been associated with the activity and modulation of ECS in pancreatic islets. However, according to the animal model and experimental design, either endogenous or pharmacological ligands of cannabinoid receptors have guided to contradictory and paradoxical results that suggest a complex physiological interaction. In consensus, ECS activity modulates insulin and glucagon secretions according to glucose in media; over-stimulation of cannabinoid receptors affects islets negatively, leading to glucose intolerance, meanwhile the treatment with antagonists in diabetic models and humans suggests an improvement in islets function. Graphical Abstract

15 October 2025 in Ageing Research Reviews
Verified
Journal Article
Open access
KLKaren León-Arcia
Karen León-Arcia
JAJesús Andrade-Guerrero
Jesús Andrade-Guerrero
Humberto Martínez OrozcoHumberto Martínez Orozco
Humberto Martínez Orozco
MVMarcos M. Villegas-Rojas
Marcos M. Villegas-Rojas
IPIsaac Pérez-Segura
Isaac Pérez-Segura
Luis O. Soto-RojasLuis O. Soto-Rojas
Luis O. Soto-Rojas
This systematic review investigates the timeline of Alzheimer's disease (AD)-like changes in the intracerebroventricular streptozotocin (ICV-STZ) rat model, a key tool for studying sporadic, non-genetic forms of AD. Following PRISMA guidelines, we analyzed 402 studies to characterize the progression of key pathological features, including cognitive deficits, insulin resistance, neurodegeneration, neuroinflammation, oxidative stress, tau pathology, amyloid aggregation, blood-brain barrier (BBB) dysfunction, and alterations in the gut-brain axis. Most studies used young male Wistar rats, revealing a sex and age bias. Results show cognitive impairment beginning within the first 24 h after ICV-STZ administration and persisting beyond 121 days, accompanied by early molecular changes, including disrupted insulin signaling, apoptosis (on day 1), and oxidative stress (on day 7). These events triggered a cascade of neuroinflammation, synaptic loss, tau hyperphosphorylation, amyloid plaque formation/accumulation, and neuronal death that closely resemble human AD. This work provides the first unified time-course of these alterations, confirming the model's ability to mimic the complexity of AD, while also identifying important gaps, such as its limited use of female and aged rats, underexplored areas like the BBB and gut-brain axis, and specific brain regions that require further investigation. The sporadic AD rat model induced by ICV-STZ serves as a powerful and versatile platform for dissecting the multifactorial nature of AD, identifying early biomarkers, and accelerating the development of targeted and disease-modifying therapies.

10 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
RGRicardo Xopan Suarez Garcia
Ricardo Xopan Suarez Garcia
QCQuetzal Chavez Castañeda
Quetzal Chavez Castañeda
RPRodrigo Orrico Pérez
Rodrigo Orrico Pérez
SVSebastián Valencia-Marin
Sebastián Valencia-Marin
ACAri Evelyn Castañeda-Ramírez
Ari Evelyn Castañeda-Ramírez
HCHector Ivan Saldivar Ceron
Hector Ivan Saldivar Ceron
Effective diagnostic communication—delivering a diagnosis with clarity, structure, and empathy—remains a challenging competency for many undergraduate medical students. This single-arm pre–post study evaluated a generative artificial-intelligence (GenAI) training module designed to improve diagnostic-communication performance. Thirty clinical-phase students completed two pre-test encounters in which they disclosed a type 2 diabetes mellitus (T2DM) diagnosis to a virtual patient powered by ChatGPT (GPT-4o) and were scored with an eight-domain rubric by blinded raters. They then undertook ten asynchronous GenAI scenarios with automated natural-language feedback, followed seven days later by two post-test consultations with human standardized patients assessed in real time with the same rubric. Mean total performance increased by 36.7 points (95 % CI: 31.4–42.1; p < 0.001), and the proportion of high-performing students rose from 0 % to 70 %. Gains were significant across all domains, most notably in opening the encounter, closure, and diabetes-specific explanation. Multiple regression showed that lower baseline empathy (β = –0.41, p= 0.005) and higher digital self-efficacy (β = 0.35, p= 0.016) inde-pendently predicted greater improvement; gender displayed only a marginal effect. Cluster analysis revealed three learner profiles, with the highest-gain cluster character-ised by low empathy and high digital self-efficacy. Inter-rater reliability was excellent (ICC ≈ 0.90). These findings provide empirical evidence that GenAI-mediated practice can produce meaningful, measurable enhancements in diagnostic-communication skills and may serve as a scalable, individualised adjunct to conventional clinical education.

1 October 2024 in Cannabis & Cannabinoid Research
Verified
Journal Article
Closed access
GGGuadalupe M. Garcia-Luna
Guadalupe M. Garcia-Luna
JBJuan David Bermudes-Contreras
Juan David Bermudes-Contreras
SHSamantha Hernández-Correa
Samantha Hernández-Correa
JSJosue O. Suarez-Ortiz
Josue O. Suarez-Ortiz
DDDaniel Diaz-Urbina
Daniel Diaz-Urbina
AVAlonso Vilches-Flores
Alonso Vilches-Flores
Background: The endocannabinoid system over-activation is associated with type-2 diabetes mellitus onset, involving physiological, metabolic, and genetic alterations in pancreatic islets. The use of Δ9-Tetrahydrocannabinol (THC) as treatment is still controversial since its effects and mechanisms on insulin secretion are unclear. The aim of this study was to evaluate the effects of THC treatment in pancreatic islets from prediabetic mice. Methods: Prediabetes was induced in mice by hypercaloric diet, and then treated with THC for 3 weeks. Blood glucose and body weight were determined, after behavior tests. Histological changes were evaluated in whole pancreas; in isolated islets we analyzed the effect of THC exposure in glucose-stimulated insulin secretion (GSIS), gene expression, intracellular cyclic adenosine monophosphate (cAMP), and cytosolic calcium changes. Results: THC treatment in prediabetic mice enhanced anxiety and antidepressive behavior without changes in food ingestion, decreased oral-glucose tolerance test, plasma insulin and weight, with small alterations on pancreatic histology. In isolated islets from healthy mice THC increased GSIS, cAMP, and CB1 receptor (CB1r) expression, meanwhile calcium release was diminished. Small changes were observed in islets from prediabetic mice. Conclusions: THC treatment improves some clinical parameters in prediabetic mice, however, in isolated islets, modifies GSIS, intracellular calcium and gene expression, suggesting specific effects related to diabetes evolution.